Cargando…
Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
OBJECTIVE: The cyclicity (CIC) of cortisol spontaneously occurs in a minority of patients with Cushing syndrome (CS). When it arises, diagnostic and therapeutic approaches become more challenging. This study aimed to report a patient with Cushing disease (CD) who achieved normalization of cortisol a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Clinical Endocrinology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282527/ https://www.ncbi.nlm.nih.gov/pubmed/34307853 http://dx.doi.org/10.1016/j.aace.2021.02.007 |
_version_ | 1783723031107993600 |
---|---|
author | Machado, Márcio Carlos Cescato, Valter Angelo Sperling Fragoso, Maria Candida Barisson Villares Bronstein, Marcello Delano |
author_facet | Machado, Márcio Carlos Cescato, Valter Angelo Sperling Fragoso, Maria Candida Barisson Villares Bronstein, Marcello Delano |
author_sort | Machado, Márcio Carlos |
collection | PubMed |
description | OBJECTIVE: The cyclicity (CIC) of cortisol spontaneously occurs in a minority of patients with Cushing syndrome (CS). When it arises, diagnostic and therapeutic approaches become more challenging. This study aimed to report a patient with Cushing disease (CD) who achieved normalization of cortisol and CIC pattern with pasireotide long-acting release (pasi/LAR). METHODS: A 43-year-old female patient related an 8-month history of CS. An 8-mm pituitary nodule depicted by magnetic resonance imaging, serum cortisol suppression of >50% after 8 mg of dexamethasone therapy, and the absence of other lesions were compatible with a CD diagnosis. The patient presented with a CIC pattern with 1 episode before and 17 episodes after an unsuccessful pituitary surgery. RESULTS: Medical treatment with cabergoline alone up to 3.5 mg/wk and a combined treatment with ketoconazole 400 mg/d did not improve CIC CS. Pasi/LAR was initiated at a dose of 20 mg/mo. A few days after the first dose, the patient experienced symptoms suggestive of adrenal insufficiency. The medication and dose were maintained for 24 months. During this period, there was a normalization of UFC levels and progressive clinical improvement. Additionally, new episodes of CIC were not observed. CONCLUSION: A CD patient with a challenging issue of CIC was reported. The condition was not controlled after pituitary surgery and by the combined treatment with cabergoline and ketoconazole, although hypercortisolism was abated by the continuous use of pasi/LAR. To our knowledge, this is the first report as regards the use of this medication to control CIC in a patient with CD. |
format | Online Article Text |
id | pubmed-8282527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association of Clinical Endocrinology |
record_format | MEDLINE/PubMed |
spelling | pubmed-82825272021-07-22 Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease Machado, Márcio Carlos Cescato, Valter Angelo Sperling Fragoso, Maria Candida Barisson Villares Bronstein, Marcello Delano AACE Clin Case Rep Case Report OBJECTIVE: The cyclicity (CIC) of cortisol spontaneously occurs in a minority of patients with Cushing syndrome (CS). When it arises, diagnostic and therapeutic approaches become more challenging. This study aimed to report a patient with Cushing disease (CD) who achieved normalization of cortisol and CIC pattern with pasireotide long-acting release (pasi/LAR). METHODS: A 43-year-old female patient related an 8-month history of CS. An 8-mm pituitary nodule depicted by magnetic resonance imaging, serum cortisol suppression of >50% after 8 mg of dexamethasone therapy, and the absence of other lesions were compatible with a CD diagnosis. The patient presented with a CIC pattern with 1 episode before and 17 episodes after an unsuccessful pituitary surgery. RESULTS: Medical treatment with cabergoline alone up to 3.5 mg/wk and a combined treatment with ketoconazole 400 mg/d did not improve CIC CS. Pasi/LAR was initiated at a dose of 20 mg/mo. A few days after the first dose, the patient experienced symptoms suggestive of adrenal insufficiency. The medication and dose were maintained for 24 months. During this period, there was a normalization of UFC levels and progressive clinical improvement. Additionally, new episodes of CIC were not observed. CONCLUSION: A CD patient with a challenging issue of CIC was reported. The condition was not controlled after pituitary surgery and by the combined treatment with cabergoline and ketoconazole, although hypercortisolism was abated by the continuous use of pasi/LAR. To our knowledge, this is the first report as regards the use of this medication to control CIC in a patient with CD. American Association of Clinical Endocrinology 2021-03-09 /pmc/articles/PMC8282527/ /pubmed/34307853 http://dx.doi.org/10.1016/j.aace.2021.02.007 Text en © 2021 AACE. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Machado, Márcio Carlos Cescato, Valter Angelo Sperling Fragoso, Maria Candida Barisson Villares Bronstein, Marcello Delano Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease |
title | Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease |
title_full | Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease |
title_fullStr | Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease |
title_full_unstemmed | Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease |
title_short | Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease |
title_sort | resolution of cyclicity after pasireotide lar in a patient with cushing disease |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282527/ https://www.ncbi.nlm.nih.gov/pubmed/34307853 http://dx.doi.org/10.1016/j.aace.2021.02.007 |
work_keys_str_mv | AT machadomarciocarlos resolutionofcyclicityafterpasireotidelarinapatientwithcushingdisease AT cescatovalterangelosperling resolutionofcyclicityafterpasireotidelarinapatientwithcushingdisease AT fragosomariacandidabarissonvillares resolutionofcyclicityafterpasireotidelarinapatientwithcushingdisease AT bronsteinmarcellodelano resolutionofcyclicityafterpasireotidelarinapatientwithcushingdisease |